**DRUG DISCOVERY: THE IC50 BASIC INTRODUCTION**

Author (@slack) : Bryan Muli (@brayo)

IC50, also referred to as the half- maximal inhibitory concentration, is of key significance during the drug discovery process. IC50 is a measure of the concentration of a drug to inhibit a cellular process or biological target by half( 50%). Biological targets include microbes, enzymes, cell receptors or cells. In cancer studies, it is referred to as the potency of a chemotherapeutic drug to kill 50% of cancer cells. The IC50 is essential for understanding the biological and pharmacological properties of a chemotherapeutic drug<!--[if supportFields]><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{&quot;citationID&quot;:&quot;5k0paDoo&quot;,&quot;properties&quot;:{&quot;formattedCitation&quot;:&quot;(Aykul
&amp; Martinez-Hackert, 2016)&quot;,&quot;plainCitation&quot;:&quot;(Aykul
&amp; Martinez-Hackert, 2016)&quot;,&quot;noteIndex&quot;:0},&quot;citationItems&quot;:[{&quot;id&quot;:377,&quot;uris&quot;:[&quot;http://zotero.org/users/14310774/items/IX59GK5Y&quot;],&quot;itemData&quot;:{&quot;id&quot;:377,&quot;type&quot;:&quot;article-journal&quot;,&quot;abstract&quot;:&quot;Half-maximal
inhibitory concentration (IC50) is the most widely used and informative measure
of a drug's efficacy. It indicates how much drug is needed to inhibit a
biological process by half, thus providing a measure of potency of an
antagonist drug in pharmacological research. Most approaches to determine IC50
of a pharmacological compound are based on assays that utilize whole cell
systems. While they generally provide outstanding potency information, results
can depend on the experimental cell line used and may not differentiate a
compound's ability to inhibit specific interactions. Here we show using the
secreted Transforming Growth Factor-β (TGF-β) family ligand BMP-4 and its
receptors as example that surface plasmon resonance can be used to accurately
determine IC50 values of individual ligand-receptor pairings. The molecular
resolution achievable wih this approach can help distinguish inhibitors that
specifically target individual complexes, or that can inhibit multiple
functional interactions at the same
time.&quot;,&quot;container-title&quot;:&quot;Analytical
Biochemistry&quot;,&quot;DOI&quot;:&quot;10.1016/j.ab.2016.06.025&quot;,&quot;ISSN&quot;:&quot;1096-0309&quot;,&quot;journalAbbreviation&quot;:&quot;Anal
Biochem&quot;,&quot;language&quot;:&quot;eng&quot;,&quot;note&quot;:&quot;PMID:
27365221\nPMCID:
PMC4955526&quot;,&quot;page&quot;:&quot;97-103&quot;,&quot;source&quot;:&quot;PubMed&quot;,&quot;title&quot;:&quot;Determination
of half-maximal inhibitory concentration using biosensor-based protein
interaction analysis&quot;,&quot;volume&quot;:&quot;508&quot;,&quot;author&quot;:[{&quot;family&quot;:&quot;Aykul&quot;,&quot;given&quot;:&quot;Senem&quot;},{&quot;family&quot;:&quot;Martinez-Hackert&quot;,&quot;given&quot;:&quot;Erik&quot;}],&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2016&quot;,9,1]]}}}],&quot;schema&quot;:&quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&quot;}
<span style='mso-element:field-separator'></span></span><![endif]-->(Aykul & Martinez-Hackert, 2016)<!--[if supportFields]><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]-->.

 

**METHODS**

IC50 is quantified _in-vitro,_ biological samples outside their normal biological context. The EC50 is comparable to the IC50 in that it is obtained _in- vivo_, biological samples in their normal biological context. Most approaches to determine IC50 of a chemotherapeutic drug are based on assays that utilise whole cell systems<!--[if supportFields]><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{&quot;citationID&quot;:&quot;tYzOIoFm&quot;,&quot;properties&quot;:{&quot;formattedCitation&quot;:&quot;(Aykul
&amp; Martinez-Hackert, 2016)&quot;,&quot;plainCitation&quot;:&quot;(Aykul
&amp; Martinez-Hackert, 2016)&quot;,&quot;noteIndex&quot;:0},&quot;citationItems&quot;:[{&quot;id&quot;:377,&quot;uris&quot;:[&quot;http://zotero.org/users/14310774/items/IX59GK5Y&quot;],&quot;itemData&quot;:{&quot;id&quot;:377,&quot;type&quot;:&quot;article-journal&quot;,&quot;abstract&quot;:&quot;Half-maximal
inhibitory concentration (IC50) is the most widely used and informative measure
of a drug's efficacy. It indicates how much drug is needed to inhibit a
biological process by half, thus providing a measure of potency of an
antagonist drug in pharmacological research. Most approaches to determine IC50
of a pharmacological compound are based on assays that utilize whole cell
systems. While they generally provide outstanding potency information, results
can depend on the experimental cell line used and may not differentiate a
compound's ability to inhibit specific interactions. Here we show using the
secreted Transforming Growth Factor-β (TGF-β) family ligand BMP-4 and its receptors
as example that surface plasmon resonance can be used to accurately determine
IC50 values of individual ligand-receptor pairings. The molecular resolution
achievable wih this approach can help distinguish inhibitors that specifically
target individual complexes, or that can inhibit multiple functional
interactions at the same
time.&quot;,&quot;container-title&quot;:&quot;Analytical
Biochemistry&quot;,&quot;DOI&quot;:&quot;10.1016/j.ab.2016.06.025&quot;,&quot;ISSN&quot;:&quot;1096-0309&quot;,&quot;journalAbbreviation&quot;:&quot;Anal
Biochem&quot;,&quot;language&quot;:&quot;eng&quot;,&quot;note&quot;:&quot;PMID:
27365221\nPMCID:
PMC4955526&quot;,&quot;page&quot;:&quot;97-103&quot;,&quot;source&quot;:&quot;PubMed&quot;,&quot;title&quot;:&quot;Determination
of half-maximal inhibitory concentration using biosensor-based protein
interaction analysis&quot;,&quot;volume&quot;:&quot;508&quot;,&quot;author&quot;:[{&quot;family&quot;:&quot;Aykul&quot;,&quot;given&quot;:&quot;Senem&quot;},{&quot;family&quot;:&quot;Martinez-Hackert&quot;,&quot;given&quot;:&quot;Erik&quot;}],&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2016&quot;,9,1]]}}}],&quot;schema&quot;:&quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&quot;}
<span style='mso-element:field-separator'></span></span><![endif]-->(Aykul & Martinez-Hackert, 2016)<!--[if supportFields]><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]-->. These approaches provide outstanding potency information, however results depend on the experimental cell line used and may not differentiate a compound’s ability to inhibit specific interactions. The assays involved in determining IC50 include competitive binding and functional antagonist assays. The IC50 is expressed as micromolar (µM), nanomolar (nM) or millimolar (mM). These units depend on the potency of the compound where the lower values indicate higher potency. The IC50 is determined by exposing the cancer cells to differential drug concentrations in a 96- microwell plate. The well values should be converted to percentage inhibition or percentage activity in relation to the negative or positive control used. A dose- response curve is then constructed and the IC50  value calculated as the concentration that is needed to inhibit half of the maximum biological response of the antagonist. The curve constructed is a sigmoid and is constructed using non-linear regression and fitted to the Hill’s equation. The following is an example of concentration-response best fit by the Hill slope model.Both asymptotes are defined by the data, and the fitting error is approximately the same with all 3 models. Note that even though the fitting error is smallest with the top fixed (8.63% versus 9.51%), the reduction is not small enough to warrant the fixed top model, nor is there any material change in the IC50. The fixed bottom model is clearly inappropriate as the data clearly defines a bottom >0.<!--[if supportFields]><span
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{&quot;citationID&quot;:&quot;CdNUPFGr&quot;,&quot;properties&quot;:{&quot;formattedCitation&quot;:&quot;(Beck
et al., 2004; He et al., 2016; {\\i{}IC50 versus EC50}, 2017; Neubig et al.,
2003)&quot;,&quot;plainCitation&quot;:&quot;(Beck et al., 2004; He et al.,
2016; IC50 versus EC50, 2017; Neubig et al.,
2003)&quot;,&quot;noteIndex&quot;:0},&quot;citationItems&quot;:[{&quot;id&quot;:372,&quot;uris&quot;:[&quot;http://zotero.org/users/14310774/items/89USMU87&quot;],&quot;itemData&quot;:{&quot;id&quot;:372,&quot;type&quot;:&quot;chapter&quot;,&quot;abstract&quot;:&quot;Most
biological assays measure potency of compounds as an activity coefficient,
frequently known as molar concentration of inhibitor at 50% response (IC50) or
an agonist concentration at 50% biological activity (EC50). Since biological
response responses are non-linear and generally sigmoidal in shape, appropriate
curve fitting is important. In addition, the variability in measured IC50/EC50
should be monitored to ensure reliable and robust data analysis of the assay
curves to support expensive SAR operations in drug discovery. This chapter
addresses in detail significant concepts in curve-fitting techniques and
statistical concepts and tools required SAR
support.&quot;,&quot;call-number&quot;:&quot;NBK91994&quot;,&quot;container-title&quot;:&quot;Assay
Guidance Manual&quot;,&quot;event-place&quot;:&quot;Bethesda
(MD)&quot;,&quot;language&quot;:&quot;eng&quot;,&quot;note&quot;:&quot;PMID:
22553866&quot;,&quot;publisher&quot;:&quot;Eli Lilly &amp; Company and the
National Center for Advancing Translational
Sciences&quot;,&quot;publisher-place&quot;:&quot;Bethesda
(MD)&quot;,&quot;source&quot;:&quot;PubMed&quot;,&quot;title&quot;:&quot;Assay
Operations for SAR
Support&quot;,&quot;URL&quot;:&quot;http://www.ncbi.nlm.nih.gov/books/NBK91994/&quot;,&quot;author&quot;:[{&quot;family&quot;:&quot;Beck&quot;,&quot;given&quot;:&quot;Benoit&quot;},{&quot;family&quot;:&quot;Chen&quot;,&quot;given&quot;:&quot;Yun-Fei&quot;},{&quot;family&quot;:&quot;Dere&quot;,&quot;given&quot;:&quot;Walthere&quot;},{&quot;family&quot;:&quot;Devanarayan&quot;,&quot;given&quot;:&quot;Viswanath&quot;},{&quot;family&quot;:&quot;Eastwood&quot;,&quot;given&quot;:&quot;Brian
J.&quot;},{&quot;family&quot;:&quot;Farmen&quot;,&quot;given&quot;:&quot;Mark
W.&quot;},{&quot;family&quot;:&quot;Iturria&quot;,&quot;given&quot;:&quot;Stephen
J.&quot;},{&quot;family&quot;:&quot;Iversen&quot;,&quot;given&quot;:&quot;Phillip
W.&quot;},{&quot;family&quot;:&quot;Kahl&quot;,&quot;given&quot;:&quot;Steven
D.&quot;},{&quot;family&quot;:&quot;Moore&quot;,&quot;given&quot;:&quot;Roger
A.&quot;},{&quot;family&quot;:&quot;Sawyer&quot;,&quot;given&quot;:&quot;Barry
D.&quot;},{&quot;family&quot;:&quot;Weidner&quot;,&quot;given&quot;:&quot;Jeffrey&quot;}],&quot;editor&quot;:[{&quot;family&quot;:&quot;Markossian&quot;,&quot;given&quot;:&quot;Sarine&quot;},{&quot;family&quot;:&quot;Grossman&quot;,&quot;given&quot;:&quot;Abigail&quot;},{&quot;family&quot;:&quot;Arkin&quot;,&quot;given&quot;:&quot;Michelle&quot;},{&quot;family&quot;:&quot;Auld&quot;,&quot;given&quot;:&quot;Douglas&quot;},{&quot;family&quot;:&quot;Austin&quot;,&quot;given&quot;:&quot;Chris&quot;},{&quot;family&quot;:&quot;Baell&quot;,&quot;given&quot;:&quot;Jonathan&quot;},{&quot;family&quot;:&quot;Brimacombe&quot;,&quot;given&quot;:&quot;Kyle&quot;},{&quot;family&quot;:&quot;Chung&quot;,&quot;given&quot;:&quot;Thomas
D.
Y.&quot;},{&quot;family&quot;:&quot;Coussens&quot;,&quot;given&quot;:&quot;Nathan
P.&quot;},{&quot;family&quot;:&quot;Dahlin&quot;,&quot;given&quot;:&quot;Jayme
L.&quot;},{&quot;family&quot;:&quot;Devanarayan&quot;,&quot;given&quot;:&quot;Viswanath&quot;},{&quot;family&quot;:&quot;Foley&quot;,&quot;given&quot;:&quot;Timothy
L.&quot;},{&quot;family&quot;:&quot;Glicksman&quot;,&quot;given&quot;:&quot;Marcie&quot;},{&quot;family&quot;:&quot;Gorshkov&quot;,&quot;given&quot;:&quot;Kirill&quot;},{&quot;family&quot;:&quot;Haas&quot;,&quot;given&quot;:&quot;Joseph
V.&quot;},{&quot;family&quot;:&quot;Hall&quot;,&quot;given&quot;:&quot;Matthew
D.&quot;},{&quot;family&quot;:&quot;Hoare&quot;,&quot;given&quot;:&quot;Samuel&quot;},{&quot;family&quot;:&quot;Inglese&quot;,&quot;given&quot;:&quot;James&quot;},{&quot;family&quot;:&quot;Iversen&quot;,&quot;given&quot;:&quot;Philip
W.&quot;},{&quot;family&quot;:&quot;Lal-Nag&quot;,&quot;given&quot;:&quot;Madhu&quot;},{&quot;family&quot;:&quot;Li&quot;,&quot;given&quot;:&quot;Zhuyin&quot;},{&quot;family&quot;:&quot;Manro&quot;,&quot;given&quot;:&quot;Jason
R.&quot;},{&quot;family&quot;:&quot;McGee&quot;,&quot;given&quot;:&quot;James&quot;},{&quot;family&quot;:&quot;McManus&quot;,&quot;given&quot;:&quot;Owen&quot;},{&quot;family&quot;:&quot;Pearson&quot;,&quot;given&quot;:&quot;Mackenzie&quot;},{&quot;family&quot;:&quot;Riss&quot;,&quot;given&quot;:&quot;Terry&quot;},{&quot;family&quot;:&quot;Saradjian&quot;,&quot;given&quot;:&quot;Peter&quot;},{&quot;family&quot;:&quot;Sittampalam&quot;,&quot;given&quot;:&quot;G.
Sitta&quot;},{&quot;family&quot;:&quot;Tarselli&quot;,&quot;given&quot;:&quot;Mike&quot;},{&quot;family&quot;:&quot;Trask&quot;,&quot;given&quot;:&quot;O.
Joseph&quot;},{&quot;family&quot;:&quot;Weidner&quot;,&quot;given&quot;:&quot;Jeffrey
R.&quot;},{&quot;family&quot;:&quot;Wildey&quot;,&quot;given&quot;:&quot;Mary
Jo&quot;},{&quot;family&quot;:&quot;Wilson&quot;,&quot;given&quot;:&quot;Kelli&quot;},{&quot;family&quot;:&quot;Xia&quot;,&quot;given&quot;:&quot;Menghang&quot;},{&quot;family&quot;:&quot;Xu&quot;,&quot;given&quot;:&quot;Xin&quot;}],&quot;accessed&quot;:{&quot;date-parts&quot;:[[&quot;2024&quot;,9,3]]},&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2004&quot;]]}}},{&quot;id&quot;:375,&quot;uris&quot;:[&quot;http://zotero.org/users/14310774/items/DSIFRXQM&quot;],&quot;itemData&quot;:{&quot;id&quot;:375,&quot;type&quot;:&quot;article-journal&quot;,&quot;abstract&quot;:&quot;Inconsistencies
in the half-maximal (50%) inhibitory concentration (IC50) data for anticancer
chemotherapeutic agents have yielded irreproducible experimental results and
thus reciprocally contradictory theories in modern cancer research. The MTT
assay is currently the most extensively used method for IC50 measurements.
Here, we dissected the critical reasons behind MTT-dependent IC50
inconsistencies. We showed that IC50 errors caused by the technical
deficiencies of the MTT assay are large and not adjustable (range:
300–11,000%). To overcome severe MTT artifacts, we developed an unbiased direct
IC50 measurement method, the limiting dilution assay. This detection technique
led us to the discovery of the inherent density-dependent chemoresistance
variation of cancer cells, which is manifold and unpredictable in its forms.
The subsequent intracellular signaling pathway analysis indicated that pAkt and
p62 expression levels correlated with alterations in the IC50 values for
cisplatin in ovarian cancer, providing an explainable mechanism for this
property. An in situ pAkt-and-p62-based immunohistochemical (IHCpAkt+p62)
scoring system was thereby established. Both the limiting dilution assay and
the IHCpAkt+p62 scoring system accurately predicted the primary chemoresistance
against cisplatin in ovarian cancer patients. Furthermore, two distinct
chemoresistant recurrence patterns were uncovered using these novel detection
tools, which were linked to two different forms of density-chemoresistance
relationships (positively vs. negatively correlated), respectively. An
interpretation was given based on the cancer evolution theory. We concluded
that the density-related IC50 uncertainty is a natural property of the cancer
cells and that the precise measurement of the density-dependent IC50 spectrum
can benefit both basic and clinical cancer research fields.&quot;,&quot;container-title&quot;:&quot;Oncotarget&quot;,&quot;DOI&quot;:&quot;10.18632/oncotarget.12223&quot;,&quot;ISSN&quot;:&quot;1949-2553&quot;,&quot;issue&quot;:&quot;43&quot;,&quot;journalAbbreviation&quot;:&quot;Oncotarget&quot;,&quot;note&quot;:&quot;PMID:
27683123\nPMCID:
PMC5342590&quot;,&quot;page&quot;:&quot;70803-70821&quot;,&quot;source&quot;:&quot;PubMed
Central&quot;,&quot;title&quot;:&quot;The changing 50% inhibitory concentration
(IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the
precise measurement of density-dependent chemoresistance in ovarian
cancer&quot;,&quot;title-short&quot;:&quot;The changing 50% inhibitory
concentration (IC50) of cisplatin&quot;,&quot;volume&quot;:&quot;7&quot;,&quot;author&quot;:[{&quot;family&quot;:&quot;He&quot;,&quot;given&quot;:&quot;Yifeng&quot;},{&quot;family&quot;:&quot;Zhu&quot;,&quot;given&quot;:&quot;Qiujing&quot;},{&quot;family&quot;:&quot;Chen&quot;,&quot;given&quot;:&quot;Mo&quot;},{&quot;family&quot;:&quot;Huang&quot;,&quot;given&quot;:&quot;Qihong&quot;},{&quot;family&quot;:&quot;Wang&quot;,&quot;given&quot;:&quot;Wenjing&quot;},{&quot;family&quot;:&quot;Li&quot;,&quot;given&quot;:&quot;Qing&quot;},{&quot;family&quot;:&quot;Huang&quot;,&quot;given&quot;:&quot;Yuting&quot;},{&quot;family&quot;:&quot;Di&quot;,&quot;given&quot;:&quot;Wen&quot;}],&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2016&quot;,9,23]]}}},{&quot;id&quot;:389,&quot;uris&quot;:[&quot;http://zotero.org/users/14310774/items/XRKP7H3K&quot;],&quot;itemData&quot;:{&quot;id&quot;:389,&quot;type&quot;:&quot;webpage&quot;,&quot;title&quot;:&quot;IC50
versus
EC50&quot;,&quot;URL&quot;:&quot;https://web.archive.org/web/20170528053210/https://www.fda.gov/ohrms/dockets/ac/00/slides/3621s1d/sld036.htm&quot;,&quot;accessed&quot;:{&quot;date-parts&quot;:[[&quot;2024&quot;,9,3]]},&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2017&quot;,5,28]]}}},{&quot;id&quot;:383,&quot;uris&quot;:[&quot;http://zotero.org/users/14310774/items/5DY5YXVG&quot;],&quot;itemData&quot;:{&quot;id&quot;:383,&quot;type&quot;:&quot;article-journal&quot;,&quot;abstract&quot;:&quot;The
recommendations that follow have been updated from the proposals of a Technical
Subcommittee set up by the International Union of Pharmacology Committee on
Receptor Nomenclature and Drug Classification (Jenkinson DH, Barnard EA, Hoyer
D, Humphrey PPA, Leff P, and Shankley NP (1995) International Union of
Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX.
Recommendations on terms and symbols in quantitative pharmacology. Pharmacol
Rev 47:255–266).&quot;,&quot;container-title&quot;:&quot;Pharmacological
Reviews&quot;,&quot;DOI&quot;:&quot;10.1124/pr.55.4.4&quot;,&quot;ISSN&quot;:&quot;0031-6997,
1521-0081&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;journalAbbreviation&quot;:&quot;Pharmacol
Rev&quot;,&quot;language&quot;:&quot;en&quot;,&quot;license&quot;:&quot;The
American Society for Pharmacology and Experimental
Therapeutics&quot;,&quot;note&quot;:&quot;publisher: American Society for
Pharmacology and Experimental Therapeutics\nsection: Review\nPMID:
14657418&quot;,&quot;page&quot;:&quot;597-606&quot;,&quot;source&quot;:&quot;pharmrev.aspetjournals.org&quot;,&quot;title&quot;:&quot;International
Union of Pharmacology Committee on Receptor Nomenclature and Drug
Classification. XXXVIII. Update on Terms and Symbols in Quantitative
Pharmacology&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;author&quot;:[{&quot;family&quot;:&quot;Neubig&quot;,&quot;given&quot;:&quot;Richard
R.&quot;},{&quot;family&quot;:&quot;Spedding&quot;,&quot;given&quot;:&quot;Michael&quot;},{&quot;family&quot;:&quot;Kenakin&quot;,&quot;given&quot;:&quot;Terry&quot;},{&quot;family&quot;:&quot;Christopoulos&quot;,&quot;given&quot;:&quot;Arthur&quot;}],&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2003&quot;,12,1]]}}}],&quot;schema&quot;:&quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&quot;}
<span style='mso-element:field-separator'></span></span><![endif]-->(Beck et al., 2004; He et al., 2016; _IC50 versus EC50_, 2017; Neubig et al., 2003)<!--[if supportFields]><span style='font-size:12.0pt;line-height:
107%;font-family:"Times New Roman",serif'><span style='mso-element:field-end'></span></span><![endif]--> 

<!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfPZMIN0LXeg6yhIC187AKAmYyiwlQPIF3zN2Ljc4bpTUKwGkZTmZb21AqTE_QHeMFiaUBFKvekyEMZuqeFMWGnRd0mUvT1WwlyKKfW8HBC73LxMcG9NBaVp_KVGUBEsI7KY-62Gif-DA0YcvhwKQwU-kX1?key=P2BSZ5dmPgxqXiOb20Ec2w"
 style='width:451.5pt;height:419.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ADMIN/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="AD_4nXfPZMIN0LXeg6yhIC187AKAmYyiwlQPIF3zN2Ljc4bpTUKwGkZTmZb21AqTE_QHeMFiaUBFKvekyEMZuqeFMWGnRd0mUvT1WwlyKKfW8HBC73LxMcG9NBaVp_KVGUBEsI7KY-62Gif-DA0YcvhwKQwU-kX1?key=P2BSZ5dmPgxqXiOb20Ec2w"/>
</v:shape><![endif]--><!--[if !vml]-->![https://lh7-rt.googleusercontent.com/docsz/AD\_4nXfPZMIN0LXeg6yhIC187AKAmYyiwlQPIF3zN2Ljc4bpTUKwGkZTmZb21AqTE\_QHeMFiaUBFKvekyEMZuqeFMWGnRd0mUvT1WwlyKKfW8HBC73LxMcG9NBaVp\_KVGUBEsI7KY-62Gif-DA0YcvhwKQwU-kX1?key=P2BSZ5dmPgxqXiOb20Ec2w](file:///C:/Users/ADMIN/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg)<!--[endif]-->

 

The hill equation is represented as the following

Y= bottom+(top- bottom1+(IC50X)n)

- **Y** is the response (e.g., percent inhibition).
- **Bottom** and **Top** are the minimum and maximum response values.
- **Hill Slope** describes the steepness of the curve.
- **X **is the drug concentration

There are softwares developed like GraphPad prism that also calculate the IC50 accurately.

**CONCLUSION**

The IC50 is an essential unit that is used to measure a drug’s potency and selectivity thus aiding in the drug discovery process. It is useful in eliminating drugs that lack sufficient potency with only the most effective advancing to the other drug discovery process. This helps to create safer drugs that are effective at combating cancer.

 

**REFERENCES **

<!--[if !supportLists]-->1.      <!--[endif]--><!--[if supportFields]><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>ADDIN ZOTERO_BIBL
{&quot;uncited&quot;:[],&quot;omitted&quot;:[],&quot;custom&quot;:[]}
CSL_BIBLIOGRAPHY <span style='mso-element:field-separator'></span><![endif]-->Aykul, S., & Martinez-Hackert, E. (2016). Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. _Analytical Biochemistry_, _508_, 97–103. https\://doi.org/10.1016/j.ab.2016.06.025

<!--[if !supportLists]-->2.      <!--[endif]-->Beck, B., Chen, Y.-F., Dere, W., Devanarayan, V., Eastwood, B. J., Farmen, M. W., Iturria, S. J., Iversen, P. W., Kahl, S. D., Moore, R. A., Sawyer, B. D., & Weidner, J. (2004). Assay Operations for SAR Support. In S. Markossian, A. Grossman, M. Arkin, D. Auld, C. Austin, J. Baell, K. Brimacombe, T. D. Y. Chung, N. P. Coussens, J. L. Dahlin, V. Devanarayan, T. L. Foley, M. Glicksman, K. Gorshkov, J. V. Haas, M. D. Hall, S. Hoare, J. Inglese, P. W. Iversen, … X. Xu (Eds.), _Assay Guidance Manual_. Eli Lilly & Company and the National Center for Advancing Translational Sciences. http\://www\.ncbi.nlm.nih.gov/books/NBK91994/

<!--[if !supportLists]-->3.      <!--[endif]-->He, Y., Zhu, Q., Chen, M., Huang, Q., Wang, W., Li, Q., Huang, Y., & Di, W. (2016). The changing 50% inhibitory concentration (IC50) of cisplatin: A pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. _Oncotarget_, _7_(43), 70803–70821. https\://doi.org/10.18632/oncotarget.12223

<!--[if !supportLists]-->4.      <!--[endif]-->_IC50 versus EC50_. (2017, May 28). https\://web.archive.org/web/20170528053210/https\://www\.fda.gov/ohrms/dockets/ac/00/slides/3621s1d/sld036.htm

<!--[if !supportLists]-->5.      <!--[endif]-->Neubig, R. R., Spedding, M., Kenakin, T., & Christopoulos, A. (2003). International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. _Pharmacological Reviews_, _55_(4), 597–606. https\://doi.org/10.1124/pr.55.4.4

<!--[if supportFields]><span style='font-size:12.0pt;line-height:107%;
font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><span style='mso-element:field-end'></span></span><![endif]-->
